Veeva Introduces New Capabilities for Remote Drug Sampling in Veeva CRM Engage Meeting
Veeva Systems (NYSE: VEEV) today introduced new remote sampling capabilities in Veeva CRM Engage Meeting. Remote sampling enables field reps to capture and fulfill healthcare professionals’ (HCPs) sample requests, also known as business reply cards (BRCs), while hosting an online meeting. Now companies can complete drug sampling processes during remote meetings in compliance with 21 CFR Part 11 and PDMA requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200422005405/en/
Doctors can request product samples from field reps through any mobile device or browser. (Graphic: Business Wire)
“Veeva CRM Engage Meeting is powering new ways of working remotely so field reps can help physicians maintain continuity in patient care,” said Arno Sosna, general manager of Veeva CRM. “Our dedication to product excellence and rapid innovation helps Veeva customers quickly deploy new digital capabilities and channels.”
Veeva CRM Engage Meeting makes online meetings with healthcare providers easy and compliant and, now with remote sampling, companies can deliver drug samples without the need for a face-to-face meeting. Reps can confirm license and address information, validate sample details, and save HCP signatures as part of the call record – the same compliant process they would follow during an in-person meeting. HCP signatures can be captured online across any mobile device or browser.
Remote medical inquiry management and consent management are also planned for Veeva CRM Engage Meeting. These new capabilities will allow field reps to compliantly capture and respond to HCP medical inquiries and enable HCPs to approve their communication preferences using Veeva CRM Engage Meeting.
These latest innovations will continue to help the industry in its rapid shift to digital. Since March 2020, Veeva has offered Veeva CRM Engage Meeting free to new customers so they can stay connected with HCPs. During March, life sciences companies connected with more than 100,000 HCPs online,1 up 2,347% compared to January. These remote meetings are also more in-depth, lasting an average of 13 minutes longer2 than a typical face-to-face meeting.3
Remote sampling is available today in Veeva CRM Engage Meeting. Remote medical inquiry management and remote consent are expected to be available in the coming months. To learn more about Veeva CRM Engage Meeting, visit veeva.com/eu/engage-meeting.
Learn how Veeva is helping customers leverage digital to connect with HCPs at the upcoming Veeva Summit on 9 June, 2020. Pre-register for the virtual event and stay up-to-date on program details at veeva.com/Summit.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 850 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
1 Based on internal data from Veeva HCP Pulse
2 Based on internal data from Veeva HCP Pulse
3
Pharma Sales Reps are Struggling – Here’s Why. BlueNovius. May 2018.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200422005405/en/
Contact information
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Suzano Reports Record First-Quarter Revenue9.5.2025 03:12:00 EEST | Press release
Suzano, the world’s largest pulp producer, announces its first quarter results for 2025 (1Q25) with record net revenue of R$11.6 billion, up 22% on the same quarter last year (1Q24). The result was driven by the exchange rates, increased pulp sales volumes from the new Ribas do Rio Pardo mill, higher paper volume and prices and the positive contribution from our paperboard mills recently acquired in the U.S. The record revenues occurred despite a series of planned downtimes in the quarter, including production lines of the Três Lagoas Unit, Mucuri Unit, and Aracruz Unit, and the Ribas do Rio Pardo Unit’s first scheduled maintenance downtime. Sales exceeded 3 million tonnes in the quarter, a rise of 12% compared to 1Q24, comprising 2.7 million tonnes of pulp and 390 thousand tonnes of paper, up 10% and 25%, respectively, on the same quarter last year. Adjusted EBITDA totaled R$4.9 billion, a 7% increase over 1Q24. Operating cash generation totaled R$2.6 billion, rising 5% on 1Q24. Net p
GC Aesthetics® Strengthens Board of Directors with Strategic Appointments8.5.2025 18:10:00 EEST | Press release
GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets is pleased to announce the appointment of Mr. Luigi Ferrari as Chairman of the Board (non-executive) and Mr. Patrick Lee as Board Director, reinforcing the company’s strategic direction and long-term growth plans. These appointments follow the renewed phase of partnership initiated in early 2024 with Hayfin Capital Management, a longstanding investor in GCA. This collaboration has brought fresh momentum to the company’s commitment to innovation, safety, and global expansion in aesthetic and reconstructive breast surgery. Luigi Ferrari, a seasoned executive and investor with a proven track record in the healthcare sector, brings deep leadership experience, commercial growth expertise and industry insight. From 2012 to 2022 he was CEO of Lima Corporate, a global medical device company in the joint replacement market, acquired then by Enovis Corp
PPG to invest $380 million to build new U.S. manufacturing facility in Shelby, N.C. for aerospace coatings and sealants8.5.2025 17:30:00 EEST | Press release
PPG (NYSE: PPG) today announced that it will invest $380 million to build a new aerospace coatings and sealants manufacturing facility in Shelby, N.C. Construction on the 62-acre site, which will initially include manufacturing and warehousing units, is set to commence in October 2025 and is expected to be completed in the first half of 2027. The 198,000-square-foot facility will enable the company to continue meeting the growing demands of the aerospace industry. It will employ more than 110 people and produce the full line of PPG’s aerospace coatings and sealants. The additional capacity of this new plant, combined with nearby transport links that improve supply chain and shipping logistics, will help improve service levels for customers. “PPG’s investment in this new manufacturing facility demonstrates the significant demand growth for our world-class technologies and our continued commitment to serving our aerospace customers,” said Tim Knavish, PPG chairman and chief executive off
WHOOP Unveils WHOOP® 5.0 and WHOOP® MG: Powerful New Devices with Breakthrough Health and Longevity Features8.5.2025 17:00:00 EEST | Press release
WHOOP, the human performance company, today introduces WHOOP 5.0 and WHOOP MG — two next-generation wearables designed to unlock a new approach to personal health and longevity. Paired with a redesigned WHOOP experience, the devices offer 14-day battery life in a sleeker, seven percent smaller form - and introduce category-defining features, including Healthspan with WHOOP Age, Heart Screener with on-demand ECG, Blood Pressure Insights, and more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508546933/en/ WHOOP Unveils Next Generation WHOOP® 5.0 and WHOOP® MG These innovations arrive at a pivotal moment when ailing health systems cost more and deliver less. WHOOP is advancing a new solution and a better way - one that empowers people to connect their daily decisions to performance and health outcomes that can be measured and felt. While others track surface-level trends, WHOOP delivers longevity through depth — translati
Seoul Semiconductor Closes in on OSRAM for Global No.28.5.2025 16:00:00 EEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a leading global innovator of LED products and technology, announced that it has achieved a remarkable milestone by maintaining stable growth despite a downturn in the LED industry, narrowing the market share gap with global No.2 player ams OSRAM to just 1 percentage point. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508658995/en/ "2024 Global LED Market Share Rankings" (Source: Omdia) (Image: Seoul Semiconductor) According to the recently published “2024 Global LED Market Share Rankings” by market research firm Omdia, Seoul Semiconductor was the only company among the global top three to sustain both revenue and market share, while industry leaders Nichia and ams OSRAM experienced significant revenue declines amid the market slowdown. This achievement is underpinned by Seoul Semiconductor’s robust technological competitiveness, driven by its commitment to innovation even
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom